Lead Product(s) : MVA.HTI,ChAdOx1.HTI,Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Gilead Buys HIV Vaccine from Biotech Following Clinical Collab
Details : The acquisition of the investigational assets for the HTI therapeutic vaccine, MVA.HTI, by Gilead Sciences marks a milestone in HIV research.
Product Name : MVA.HTI
Product Type : Vaccine
Upfront Cash : Undisclosed
November 25, 2024
Lead Product(s) : MVA.HTI,ChAdOx1.HTI,Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Protein Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AEMPS Authorizes Phase III Clinical Trial of the Hipra’s Vaccine Against Covid-19
Details : Messenger RNA based Covid Vaccine is an adjuvanted recombinant protein vaccine based on a receptor-binding domain (RBD) fusion heterodimer containing variants alpha and beta of SARS-CoV-2 is authorized for phase III clinical trial.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 02, 2022
Lead Product(s) : Protein Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Messenger RNA Based COVID Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AEMPS Authorizes Phase IIb Clinical Trial of HIPRA Covid-19 Vaccine
Details : The main objectives of the Phase IIb trial are to confirm safety and tolerability for a booster dose and to check if the booster dose prolongs the immune response to Covid-19 in people who have already been vaccinated.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : Messenger RNA Based COVID Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HTI-based vaccines as a component of combination cure regimens are being evaluated in the ongoing AELIX-003 clinical trial testing HTI in combination with Gilead’s investigational TLR7 agonist vesatolimod, in people living with HIV on ART.
Product Name : GS-9620
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2021
Lead Product(s) : Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission.
Product Name : Aplidin
Product Type : Peptide
Upfront Cash : Inapplicable
April 28, 2020
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vafidemstat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORYZON has received approval from the Spanish Drug Agency to conduct a Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients.
Product Name : ORY-2001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2020
Lead Product(s) : Vafidemstat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaMar has submitted a Phase II clinical trial of Aplidin for the treatment of COVID-19
Details : The goal of the trial is to evaluate the efficacy and safety of plitidepsin in hospitalized patients as a treatment for COVID-19 (SARS-CoV-2).
Product Name : Aplidin
Product Type : Peptide
Upfront Cash : Inapplicable
February 04, 2020
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable